Northwest Biotherapeutics, Inc. (NWBO)
| Market Cap | 1.10B |
| Revenue (ttm) | 960,000 |
| Net Income (ttm) | -536.47M |
| Shares Out | 834.61M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $1.26 |
| Previous Close | $1.33 |
| Change ($) | -0.07 |
| Change (%) | -5.26% |
| Day's Open | 1.34 |
| Day's Range | 1.25 - 1.35 |
| Day's Volume | 2,529,190 |
| 52-Week Range | 0.29 - 2.51 |
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Looking for 7 penny stocks that could be buy the dip candidates? Check these out The post 7 Penny Stocks to Watch With Crypto News Sparking a Market Dip appeared first on Penny Stocks to Buy, Picks, New...
BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...
BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
With Data Lock just announced, Top Line Date is imminent.
About NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The compa... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Linda Powers | Employees 19 |
| Stock Exchange OTCMKTS | Ticker Symbol NWBO |
Financial Performance
In 2020, NWBO's revenue was $1.29 million, a decrease of -46.43% compared to the previous year's $2.41 million. Losses were -$529.82 million, 2,445.7% more than in 2019.